that methylation of individual CpG sites in CpG-poor promoters (as occurs in the NES1 gene) can determine the transcriptional status of a gene, probably by blocking the access of certain transcription factors that are sensitive to the methylation of isolated CpG sites in their target binding sites.
The loss of expression of NES1 has been demonstrated to be associated with disease progression in patients with solid tumors, including breast and prostate cancers. However, methylation status of the NES1 gene and the prognostic value of NES1 abnormalities in ALL have not been studied previously. In the present study, we demonstrated that hypermethylation of the NES1 gene provides important prognostic information in ALL patients. Methylation of the NES1 gene is a factor of poor prognosis in both childhood and adult ALL. Patients with methylation of the NES1 had a poorer DFS than nonmethylated patients. Multivariate analysis confirmed that methylation of the NES1 gene was associated with shorter DFS. However, at present, it is not clear how NES1 might function as a tumor suppressor and might influence the outcome of ALL patients. The primary sequence of NES1 predicted a serine protease. However, Dhar et al 7 were unable to detect this activity using a variety of biochemical approaches. As NES1 is a secreted protein, it probably functions extracellularly as a regulator of cell growth and/or differentiation in an autocrine or paracrine manner. 8 Although additional studies are required to define the biological function of NES1, our present study supports the notion that the NES1 gene is subject to methylation regulation at the transcriptional level in ALL cells, and that this methylation plays a role in the clinical behavior of the disease. Although the treatment outcome of children with acute lymphoblastic leukemia (ALL) has markedly improved over the past 30 years, the prognosis of infants less than 12 or 18 months of age is still disappointing. In order to improve the outcome of infant ALL, new prognostic factors should be elucidated to better stratify high-risk patients and to introduce more effective therapy. Apoptosis is a basic mechanism regulating cellular growth and differentiation. This process is controlled by a highly organized network of a variety of genes identified as positive and negative regulators responding to several stimuli from either inside or outside of the cell. The disruption of apoptosis machinery plays an important role in both leukemogenesis and drug resistance of leukemic cells. In this study, we determined the mRNA contents of representative apoptosisassociated genes (Fas, Toso, DcR3: decoy receptor 3, caspase-3; HIAP2: human inhibitor of apoptosis protein 2; Apaf-1: apoptotic protease-activating factor-1, Bcl-2a and Bcl-2b) in blasts of infant ALL and evaluated the associations of the amount of gene expression with characteristics of infants with ALL including their treatment outcome. We analyzed bone marrow samples obtained at diagnosis from 33 patients (male 15, female 18) with infant ALL by real-time quantitative RT-PCR. Ages of the patients at diagnosis ranged from 0 to 17 months (median 5 months). The patients were treated in accordance with the Japan Infant Leukemia Protocol, MLL 96.
Correlation of patients' clinical and laboratory characteristics with mRNA contents of apoptosis-associated genes Figure 1 shows the mRNA contents of apoptosis-associated genes in the leukemic blasts. The expression levels of each gene varied over a more than 10-fold range between specimens. We first examined the correlation between patients' clinical and laboratory characteristics and mRNA content of each apoptosisassociated gene (Table 1 ). The mRNA expression of Fas was significantly high in patients with MLL gene rearrangement (P ¼ 0.04). In addition, a low expression of HIAP2 was significantly associated with the occurrence of induction failure or relapse (P ¼ 0.02). The mRNA expression of Bcl-2a was significantly high in patients diagnosed before 6 months of age and those with MLL gene rearrangement (P ¼ 0.02 and 0.01, respectively).
Association of clinical characteristics and mRNA contents of apoptosis-associated genes with relapse-free survival (RFS) rates
Patients were divided into two groups according to the median mRNA value of each apoptosis-associated gene expression, and the RFS rates were compared between the two patient groups. The 3-year RFS rate in all 33 patients was 43.379.4% at the median follow-up period of 38 months (range 26-56 months). Table 2 shows the results of univariate analyses. The RFS rate of patients with a WBC count X200 Â 10 9 /l was significantly worse than that of patients with a low WBC count (24.6 vs 60.6%, P ¼ 0.019). The analysis examining the effect of mRNA contents of apoptosis-associated genes on RFS showed that patients with each of a low mRNA expression of Fas or HIAP2 had significantly lower RFS rate (P ¼ 0.037 and 0.043, Figure 2a and b). The Fas mRNA levels of two patients with induction failure were much lower than the median value (0.061 and 0.099, Figure 1 ). In addition, the RFS rate in patients with a low mRNA expression of Apaf-1 was lower than that in those with high expression, although it was not statistically significant (P ¼ 0.068, Figure 2c ). We then examined the independent contribution of each factor such as sex, age at diagnosis, MLL gene rearrangement, WBC count at diagnosis, and the mRNA contents of Fas, HIAP2 and Apaf-1 to the RFS rates. Multivariate analysis using Cox's proportional-hazards model demonstrated that a low mRNA level of Fas was a significant predictor of induction failure and relapse (estimated relative risk 2.77, P ¼ 0.043, Table 3 ). Another significant factor was a high WBC count (X200 Â 10 9 /l) at diagnosis (estimated relative risk 2.98, P ¼ 0.045).
Discussion
Recent studies have indicated that chemotherapeutic agents induce apoptosis in human leukemic cell lines in vitro and in clinical leukemia in vivo. The ability to undergo apoptotic cell death was reported to be associated with good prognosis in children with ALL and hyperdiploid karyotypes, a favorable characteristics in childhood ALL. 1 Leukemic cells of these patients show a marked propensity to undergo apoptosis, and their treatment outcome is usually favorable. We thus hypothesized in this study that aberrant regulation of apoptosis in leukemic cells of infant ALL would result in their hyposensitivity to apoptotic stimuli and resistance to cytotoxic drugs, therefore worsening clinical outcome. The results showed that a low mRNA level of Fas, HIAP2 or Apaf-1 in leukemic cells was associated with a low RFS rate in infant ALL. Of these, the Fas mRNA level was an independent prognostic factor by the multivariate analysis.
Binding of Fas ligand to Fas induces cleavage of procaspase-8 to an active form via Fas-associating death domain protein (FADD protein), leading to the proteolytical activation of downstream caspases including caspase-9. In acute myelogenous leukemia, Fas expression was shown to be correlated with response to chemotherapy. 2 In childhood ALL, one report claimed that Fas expression on blasts was positively correlated with the duration of complete remission. 3 However, negative results between Fas expression and patients' prognosis have also been reported. Wuchter et al 4 did not find any correlation between constitutive Fas expression and clinical characteristics of patients including treatment outcome in childhood ALL. In CML study, high Fas levels in the blasts were associated with poor prognosis. 5 The inhibitors of apoptosis (IAPs) such as XIAP, HIAP1, HIAP2 and survivin are cellular proteins homologous to baculovirus IAP protein, and reported to bind and inhibit caspase-3 and -9, thus blocking downstream apoptotic events. In one of the previous studies, higher levels of HIAP2 protein were associated with resistance to several anticancer drugs in tumor cell lines. 6 In this study, however, patients with high mRNA level of HIAP2 showed better survival than those with a low expression. As the mRNA expression levels of HIAP2 also show strong positive correlation with those of caspase-3 (r 2 ¼ 0.90, Po0.0001) (data not shown), high HIAP2 mRNA levels may have resulted from the secondary (compensatory) mechanism responding to the increased levels of caspase-3. A recent report using XIAPknockout mice showed that the levels of HIAP1 and HIAP2 protein were increased compared with wild-type mice. 7 This suggests that there exists a compensatory mechanism that leads to the upregulation of other members of IAPs family when XIAP expression is lost. Clem et al 8 reported that full-length HIAP2 Figure 1 Analyses of apoptosis-associated gene expressions in the blasts of infant ALL using real-time quantitative RT-PCR. The mRNA contents of the each apoptosis-associated gene are shown. The Y-axis indicates the relative levels of apoptosis-associated gene expression. The amount of gene expression was described as a ratio to that in PHA-stimulated normal MNCs.
Correspondence failed to protect cells from apoptosis, and that deletion of the Cterminal domain restored antiapoptotic activity, suggesting that post-translational modifications may be important for the function of HIAP2.
In case of Apaf-1, patients with high mRNA levels were marginally associated with better treatment outcome ( Table 2 and Figure 2c ). This result may be compatible with the apoptosis-inducing function of Apaf-1. Although there has been little information about the clinical significance of Apaf-1 in leukemia, some experimental studies have examined the relation of the intracellular level of Apaf-1 with chemosensitivity.
The quantitative analysis of the mRNA contents of apoptosisassociated genes in leukemic blasts may become a useful tool to predict the prognosis in infant ALL, and a low mRNA level of Fas could be an independent adverse prognostic factor. However, Table 1 Correlation between patients' clinical characteristics and expression levels of apoptosis-associated genes Correspondence recent studies have shown that the gene expression can change after drug exposure. In this study, we measured mRNA contents of apoptosis-associated genes in leukemic blasts before the beginning of the treatment. A relationship between induced levels of the apoptosis-associated genes after drug exposure and treatment results was missed in our study. Post-translational modification may also regulate the function of apoptosis. In addition, because of the limited power (n ¼ 33) of our study, the significance of Fas and HIAP2 on treatment results in infant ALL remains to be validated by further investigation.
Figure 2
Associations of the mRNA contents of apoptosisassociated genes with RFS with infant ALL. RFS rates of the patients according to the mRNA levels of Fas (a), HIAP2 (b) or Apaf-1 (c) are shown. Patients were divided into two groups based on the median mRNA value of each gene (high expression; solid line, low expression; dashed line). Table 3 Multivariate analysis for the prediction of treatment failure 
